Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
NECA Logo
  • NET Nurse
  • Donate
  • What are NETs?
    • What are Neuroendocrine Cancers?
    • What are Pheos & Paras?
    • NET Symptoms
    • NET Types
    • Causes
    • Treatments
    • Grades
    • Diagnosis
    • Prognosis
    Consider the Grey Area
  • Patients & Carers
    • Patient & Carer Support
    • Patient Resources
    • Optimal Care Pathway
    • NET Nurse
    • Patient Stories
    • Share your Story
    • Australian NET Specialists
    • Clinical Trials
    • Living with NETS
    • Specialist Support Services
    Consider the Grey Area
  • Healthcare Professionals
    • Optimal Care Pathway
    • Professional Learning
    • Patient Referral
    • Clinical Trials
    • NET Symptoms
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order Booklets & Resources
    Consider the Grey Area
  • Get Involved
    • Advocate for Us
    • Share your Story
    • Donate
    • Fundraise
    • Events
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Volunteer
    Senate MailChimp
  • NCD 2025
NET Nurse
Donate

Home » News » Clinical Cancer Research: Immunotherapy of ipilimumab and nivolumab

Clinical Cancer Research: Immunotherapy of ipilimumab and nivolumab

  • June 7, 2021
Download

Share this post

Recent posts

CommNETs 2025

December 15, 2025

NECA attends Professionals Uplifting Patient Partnership (PUPP)’s final event of the year

December 5, 2025

Navigating Extrapulmonary Neuroendocrine Carcinoma: COR2ED Resource Featuring Insights from NECA CEO Meredith Cummins

December 5, 2025

Nuclear Medicine Round Table

November 27, 2025
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousMedical imaging and nuclear Medicine: A Lancet Oncology Commission
NextNETs Q&A 2021Next

Related Posts

CommNETs 2025

The 2025 CommNETs Annual Meeting was held in Vancouver on 5–6 December, bringing together neuroendocrine cancer specialists from across Commonwealth countries. CommNETs (Commonwealth Neuroendocrine Tumour

Navigating Extrapulmonary Neuroendocrine Carcinoma: COR2ED Resource Featuring Insights from NECA CEO Meredith Cummins

Nuclear Medicine Round Table

On Monday 17 November NECA attended the National Roundtable – Sustainable Pathways: Shaping the Future of Nuclear Medicines in Australia at Parliament House. Nuclear Medicine

Celebrated Chef and Slow Food Pioneer Skye Gyngell Passed Away from Neuroendocrine Cancer

Australian born chef Skye Gyngell, one of the most influential voices in the slow food movement and a pioneer of seasonal, sustainable cooking, has died

View All

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Patients & Carers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

Healthcare Professionals

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2025 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin